APH04935

Primary Study Objective: To evaluate the safety and tolerability of APH04935 tablets after a single oral dose (SAD) in healthy adult participants and after multiple oral doses (MAD) in overweight or obese participants. Secondary Study Objectives: 1) To evaluate the pharmacokinetic characteristics of APH04935 tablets after a single oral dose in healthy adult participants and after multiple oral doses in overweight or obese participants; 2) To evaluate the effect of food on the pharmacokinetics of APH04935 tablets after a single oral dose in healthy adult participants; 3) To evaluate the pharmacodynamic effects of APH04935 tablets after multiple oral doses in overweight or obese participants. Exploratory Study Objectives: 1) To evaluate the effect of oral administration of APH04935 tablets on the QT/QTc interval in participants; 2) To explore the metabolism of APH04935 tablets in humans; 3) If data permit, to explore the relationship between drug exposure and pharmacodynamics (pharmacodynamic parameters, safety parameters) using population pharmacokinetic (PopPK) analysis.